|Articles|April 15, 2013
Open Innovation: Transforming the Model of Biopharmaceutical R&D
Don Frail, Vice President, AstraZeneca Innovative Medicines Group discusses the company's approach to innovation and the upcoming session at the BIO International Convention
Advertisement
Newsletter
Stay at the forefront of biopharmaceutical innovation—subscribe to BioPharm International for expert insights on drug development, manufacturing, compliance, and more.
Advertisement
Related Content
Advertisement
Advertisement
Advertisement
